Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics.

Tenor H, Hatzelmann A, Beume R, Lahu G, Zech K, Bethke TD.

Handb Exp Pharmacol. 2011;(204):85-119. doi: 10.1007/978-3-642-17969-3_3. Review.

PMID:
21695636
2.

Phosphodiesterase inhibitors: history of pharmacology.

Schudt C, Hatzelmann A, Beume R, Tenor H.

Handb Exp Pharmacol. 2011;(204):1-46. doi: 10.1007/978-3-642-17969-3_1. Review.

PMID:
21695634
3.

The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion.

Selige J, Hatzelmann A, Dunkern T.

J Cell Physiol. 2011 Aug;226(8):1970-80. doi: 10.1002/jcp.22529.

PMID:
21520048
4.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H.

Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7. Review.

PMID:
20381629
5.

A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.

Sabatini F, Petecchia L, Boero S, Silvestri M, Klar J, Tenor H, Beume R, Hatzelmann A, Rossi GA.

Pulm Pharmacol Ther. 2010 Aug;23(4):283-91. doi: 10.1016/j.pupt.2010.02.004. Epub 2010 Mar 11.

PMID:
20226872
6.

Cytokine-dependent balance of mitogenic effects in primary human lung fibroblasts related to cyclic AMP signaling and phosphodiesterase 4 inhibition.

Selige J, Tenor H, Hatzelmann A, Dunkern T.

J Cell Physiol. 2010 May;223(2):317-26. doi: 10.1002/jcp.22037.

PMID:
20082309
7.

Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells.

Dong H, Zitt C, Auriga C, Hatzelmann A, Epstein PM.

Biochem Pharmacol. 2010 Feb 1;79(3):321-9. doi: 10.1016/j.bcp.2009.09.001. Epub 2009 Sep 6.

PMID:
19737543
8.

Phosphodiesterase 2 mediates redox-sensitive endothelial cell proliferation and angiogenesis by thrombin via Rac1 and NADPH oxidase 2.

Diebold I, Djordjevic T, Petry A, Hatzelmann A, Tenor H, Hess J, Görlach A.

Circ Res. 2009 May 22;104(10):1169-77. doi: 10.1161/CIRCRESAHA.109.196592. Epub 2009 Apr 23.

PMID:
19390057
9.

Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.

Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S.

J Pharmacol Exp Ther. 2009 Jul;330(1):54-62. doi: 10.1124/jpet.108.148742. Epub 2009 Apr 22.

PMID:
19386793
10.

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.

Cortijo J, Iranzo A, Milara X, Mata M, Cerdá-Nicolás M, Ruiz-Saurí A, Tenor H, Hatzelmann A, Morcillo EJ.

Br J Pharmacol. 2009 Feb;156(3):534-44. doi: 10.1111/j.1476-5381.2008.00041.x.

11.

Phosphodiesterase 2 inhibition diminished acute lung injury in murine pneumococcal pneumonia.

Witzenrath M, Gutbier B, Schmeck B, Tenor H, Seybold J, Kuelzer R, Grentzmann G, Hatzelmann A, van Laak V, Tschernig T, Mitchell TJ, Schudt C, Rosseau S, Suttorp N, Schütte H.

Crit Care Med. 2009 Feb;37(2):584-90. doi: 10.1097/CCM.0b013e3181959814.

PMID:
19114892
12.

Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

Sanz MJ, Cortijo J, Taha MA, Cerdá-Nicolás M, Schatton E, Burgbacher B, Klar J, Tenor H, Schudt C, Issekutz AC, Hatzelmann A, Morcillo EJ.

Br J Pharmacol. 2007 Oct;152(4):481-92. Epub 2007 Aug 20.

13.

Characterization of inhibitors of phosphodiesterase 1C on a human cellular system.

Dunkern TR, Hatzelmann A.

FEBS J. 2007 Sep;274(18):4812-24. Epub 2007 Aug 14.

14.

Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase.

Dunkern TR, Feurstein D, Rossi GA, Sabatini F, Hatzelmann A.

Eur J Pharmacol. 2007 Oct 15;572(1):12-22. Epub 2007 Jun 29.

PMID:
17659276
15.
16.

Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition.

Klein T, Eltze M, Grebe T, Hatzelmann A, Kömhoff M.

Cardiovasc Res. 2007 Jul 15;75(2):390-7. Epub 2007 Feb 28.

PMID:
17383621
17.

PKCtheta and PKA are antagonistic partners in the NF-AT transactivation pathway of primary mouse CD3+ T lymphocytes.

Hermann-Kleiter N, Thuille N, Pfeifhofer C, Gruber T, Schäfer M, Zitt C, Hatzelmann A, Schudt C, Leitges M, Baier G.

Blood. 2006 Jun 15;107(12):4841-8. Epub 2006 Mar 2.

PMID:
16514061
18.

Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.

Tait A, Luppi A, Hatzelmann A, Fossa P, Mosti L.

Bioorg Med Chem. 2005 Feb 15;13(4):1393-402.

PMID:
15670947
19.

Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.

Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Bürger A, Hatzelmann A, Tenor H, Schudt C, Krüll M, Schütte H, Hippenstiel S, Suttorp N.

Blood. 2005 May 1;105(9):3569-76. Epub 2005 Jan 13.

PMID:
15650061
21.

In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide.

Stoeck M, Riedel R, Hochhaus G, Häfner D, Masso JM, Schmidt B, Hatzelmann A, Marx D, Bundschuh DS.

J Pharmacol Exp Ther. 2004 Apr;309(1):249-58. Epub 2004 Jan 12.

PMID:
14718604
22.

Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2.

Zitt C, Strauss B, Schwarz EC, Spaeth N, Rast G, Hatzelmann A, Hoth M.

J Biol Chem. 2004 Mar 26;279(13):12427-37. Epub 2004 Jan 12.

23.

Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.

Van der Mey M, Bommelé KM, Boss H, Hatzelmann A, Van Slingerland M, Sterk GJ, Timmerman H.

J Med Chem. 2003 May 8;46(10):2008-16.

PMID:
12723963
24.

Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.

Van der Mey M, Boss H, Couwenberg D, Hatzelmann A, Sterk GJ, Goubitz K, Schenk H, Timmerman H.

J Med Chem. 2002 Jun 6;45(12):2526-33.

PMID:
12036361
25.

Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.

Van der Mey M, Boss H, Hatzelmann A, Van der Laan IJ, Sterk GJ, Timmerman H.

J Med Chem. 2002 Jun 6;45(12):2520-5.

PMID:
12036360
26.

The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo.

Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W.

J Clin Pharmacol. 2002 Mar;42(3):297-303.

PMID:
11865966
27.

Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes--functional importance of phosphodiesterase 4.

Tenor H, Hedbom E, Häuselmann HJ, Schudt C, Hatzelmann A.

Br J Pharmacol. 2002 Feb;135(3):609-18.

28.

Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones.

Van der Mey M, Hatzelmann A, Van Klink GP, Van der Laan IJ, Sterk GJ, Thibaut U, Ulrich WR, Timmerman H.

J Med Chem. 2001 Aug 2;44(16):2523-35.

PMID:
11472206
29.

Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues.

Van der Mey M, Hatzelmann A, Van der Laan IJ, Sterk GJ, Thibaut U, Timmerman H.

J Med Chem. 2001 Aug 2;44(16):2511-22.

PMID:
11472205
30.

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.

Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R.

J Pharmacol Exp Ther. 2001 Apr;297(1):280-90.

PMID:
11259555
31.

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

Hatzelmann A, Schudt C.

J Pharmacol Exp Ther. 2001 Apr;297(1):267-79.

PMID:
11259554
32.
33.

Therapeutic potential of selective PDE inhibitors in asthma.

Schudt C, Gantner F, Tenors H, Hatzelmann A.

Pulm Pharmacol Ther. 1999;12(2):123-9. Review. No abstract available.

PMID:
10373395
34.

Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

Galle J, Zabel U, Hübner U, Hatzelmann A, Wagner B, Wanner C, Schmidt HH.

Br J Pharmacol. 1999 May;127(1):195-203.

35.

Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.

Gantner F, Götz C, Gekeler V, Schudt C, Wendel A, Hatzelmann A.

Br J Pharmacol. 1998 Mar;123(6):1031-8.

36.

Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study.

Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A.

J Allergy Clin Immunol. 1997 Oct;100(4):527-35.

PMID:
9338548
38.

Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors.

Gantner F, Küsters S, Wendel A, Hatzelmann A, Schudt C, Tiegs G.

J Pharmacol Exp Ther. 1997 Jan;280(1):53-60.

PMID:
8996181
39.

Constituents of Veltheimia viridifolia; I. Homoisoflavanones of the bulbs.

Amschler G, Frahm AW, Hatzelmann A, Kilian U, Müller-Doblies D, Müller-Doblies U.

Planta Med. 1996 Dec;62(6):534-9.

PMID:
9000886
40.
41.

Automatic leukocyte differentiation in bronchoalveolar lavage fluids of guinea pigs and brown-Norway rats.

Hatzelmann A, Haefner D, Beume R, Schudt C.

J Pharmacol Toxicol Methods. 1996 Apr;35(2):91-9.

PMID:
8729435
42.

Effect of phosphodiesterase inhibition on IL-4 and IL-5 production of the murine TH2-type T cell clone D10.G4.1.

Schmidt J, Hatzelmann A, Fleissner S, Heimann-Weitschat I, Lindstaedt R, Szelenyi I.

Immunopharmacology. 1995 Sep;30(3):191-8.

PMID:
8557518
43.

Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages.

Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanović R, Schudt C, Wendel A, Church MK, Shute JK.

Clin Exp Allergy. 1995 Jul;25(7):625-33.

PMID:
8521181
44.

Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes.

Tenor H, Staniciu L, Schudt C, Hatzelmann A, Wendel A, Djukanović R, Church MK, Shute JK.

Clin Exp Allergy. 1995 Jul;25(7):616-24.

PMID:
8521180
45.
47.

PDE isoenzymes as targets for anti-asthma drugs.

Schudt C, Tenor H, Hatzelmann A.

Eur Respir J. 1995 Jul;8(7):1179-83. Review.

48.
49.

Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.

Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R.

Agents Actions. 1994 Nov;43(1-2):64-8. Review.

PMID:
7741044
50.

Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.

Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Müller-Peddinghaus R.

Biochem Pharmacol. 1994 Jul 5;48(1):31-9.

PMID:
8043028

Supplemental Content

Loading ...
Support Center